A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
National Institutes of Health Clinical Center (CC)
BigHat Biosciences, Inc.
Turning Point Therapeutics, Inc.
Revolution Medicines, Inc.
Erasca, Inc.
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Institut du Cancer de Montpellier - Val d'Aurelle
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
Intima Bioscience, Inc.
Revolution Medicines, Inc.
DualityBio Inc.